drugset / Trial / NCT05838703

Tiotropium Handihaler vs. Tiotropium Respimat in COPD

NCT05838703

Phase 2 Withdrawn Duke University
Non-randomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to determine if tiotropium Respimat will result in better ventilation distribution of the lung in COPD participants quantified by hyperpolarized XeMRI. This study is designed to simulate the real-life clinical setting where patients receive one-time instruction on the inhaler use.

Timeline

Start
2023-05-01
Primary completion
2024-05-01
Completion
2024-05-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Tiotropium Other / unclassified Inhaled